Profile state: payments and partdOpen Payments: 2025Medicare Part D: 2024Last identity check: 2026-08-10Page data build: 2026-08-12
Verified facts
What the public records show
CMS Open Payments records show Nina C Ramirez, M.D. received $192,366.68 in general payments during 2025 across 179 reported records.
AstraZeneca Pharmaceuticals LP accounted for 96.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
General Payments
$192,366.68
179 reported records · 6 companies
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
Reported company
Canonical company
Amount
Share
Records
Year
AstraZeneca Pharmaceuticals LP
Unresolved — no canonical attribution shown
$185,631.85
96.5%
164
2025
Novartis Pharmaceuticals Corporation
Unresolved — no canonical attribution shown
$2,820.94
1.5%
5
2025
GENZYME CORPORATION
Unresolved — no canonical attribution shown
$2,399.60
1.2%
7
2025
Amgen Inc.
Unresolved — no canonical attribution shown
$1,270.00
0.7%
1
2025
ARS Pharmaceuticals Operations, Inc.
Unresolved — no canonical attribution shown
$123.65
0.1%
1
2025
Genentech USA, Inc.
Unresolved — no canonical attribution shown
$120.64
0.1%
1
2025
What were the payments for?
Payment categories
Category
Amount
Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
$147,115.00
49
Travel and Lodging
$34,188.63
74
Consulting Fee
$6,694.00
5
Food and Beverage
$4,369.05
51
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
Paying company
Payment year
Drug reported by same entity
Open Payments evidence
Part D
Claims
Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference
2025
SYMBICORT open payments reported associated product
Symbicort · 2024 Exact normalized brand match · 1 Part D row
41
suppressed by CMS
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
Brand
Generic
Claims
Beneficiaries
Symbicort
Budesonide/Formoterol Fumarate
41
suppressed
Breo Ellipta
Fluticasone/Vilanterol
37
suppressed
Fluticasone Propionate
Fluticasone Propionate
33
15
Levocetirizine Dihydrochloride
Levocetirizine Dihydrochloride
27
suppressed
Trelegy Ellipta
Fluticasone/Umeclidin/Vilanter
22
suppressed
Montelukast Sodium
Montelukast Sodium
15
suppressed
Triamcinolone Acetonide
Triamcinolone Acetonide
15
suppressed
Dupixent Pen
Dupilumab
13
suppressed
Albuterol Sulfate Hfa
Albuterol Sulfate
12
suppressed
Azelastine Hcl
Azelastine Hcl
11
suppressed
Ipratropium Bromide
Ipratropium Bromide
11
suppressed
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.